ArticleAntiviral research2015
Immunobiotic Lactobacillus administered post-exposure averts the lethal sequelae of respiratory virus infection.
Article in Antiviral research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 41 citations in OpenAlex.
- Complementary Protective Effects of Lactiplantibacillus Plantarum GUANKE and Picolinic Acid Against Influenza A Virus Infection in Mice.Probiotics and antimicrobial proteins · 2026Article
- Nasal delivery ofMicrobiology spectrum · 2026Article
- Identification of immunomodulating properties of postbiotics from lactobacilli using the zebrafish (Danio rerio) model.BMC veterinary research · 2025Article
- CombinedInternational journal of molecular sciences · 2025Article
- Article
- The Mucus-Binding Factor MediatesMicroorganisms · 2024Article
- Predictors of intensive care unit length of stay and mortality among unvaccinated COVID-19 patients in Jordan.Infection prevention in practice · 2023Article
- Mortality risk and antibiotic use for COVID-19 in hospitalized patients over 80.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Article
- Targeted Delivery of Probiotics: Perspectives on Research and Commercialization.Probiotics and antimicrobial proteins · 2022Review
- The role of respiratory microbiota in the protection against viral diseases: respiratory commensal bacteria as next-generation probiotics for COVID-19.Bioscience of microbiota, food and health · 2022Review
- Ingestion, Immunity, and Infection: Nutrition and Viral Respiratory Tract Infections.Frontiers in immunology · 2022Review
- The Beneficial Role of ProbioticFrontiers in immunology · 2022Review
- Differential Expression of Mitosis and Cell Cycle Regulatory Genes during Recovery from an Acute Respiratory Virus Infection.Pathogens (Basel, Switzerland) · 2021Article
- Immunobiotic Lactobacilli Improve Resistance of Respiratory Epithelial Cells to SARS-CoV-2 Infection.Pathogens (Basel, Switzerland) · 2021Article
- Interactions between commensal bacteria and viral infection: insights for viral disease control in farmed animals.Science China. Life sciences · 2021Review
- Article
- Persistent Airway Hyperresponsiveness Following Recovery from Infection with Pneumonia Virus of Mice.Viruses · 2021Article
- Do probiotics help prevent ventilator-associated pneumonia in critically ill patients? A systematic review with meta-analysis.ERJ open research · 2021Review
- Respiratory Epithelial Cells Respond toViruses · 2020Article
- A Pragmatic Approach to Immunity & Respiratory Viral Infections.Integrative medicine (Encinitas, Calif.) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
We reported previously that priming of the respiratory tract with immunobiotic Lactobacillus prior to virus challenge protects mice against subsequent lethal infection with pneumonia virus of mice (PVM). We present here the results of gene microarray which document differential expression of proinflammatory mediators in response to PVM infection alone and those suppressed in response to Lactobacillus plantarum. We also demonstrate for the first time that intranasal inoculation with live or heat-inactivated L. plantarum or Lactobacillus reuteri promotes full survival from PVM infection when administered within 24h after virus challenge. Survival in response to L. plantarum administered after virus challenge is associated with suppression of proinflammatory cytokines, limited virus recovery, and diminished neutrophil recruitment to lung tissue and airways. Utilizing this post-virus challenge protocol, we found that protective responses elicited by L. plantarum at the respiratory tract were distinct from those at the gastrointestinal mucosa, as mice devoid of the anti-inflammatory cytokine, interleukin (IL)-10, exhibit survival and inflammatory responses that are indistinguishable from those of their wild-type counterparts. Finally, although L. plantarum interacts specifically with pattern recognition receptors TLR2 and NOD2, the respective gene-deleted mice were fully protected against lethal PVM infection by L. plantarum, as are mice devoid of type I interferon receptors. Taken together, L. plantarum is a versatile and flexible agent that is capable of averting the lethal sequelae of severe respiratory infection both prior to and post-virus challenge via complex and potentially redundant mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.